← All trials
NCT05106179
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2021
- Primary completion
- Dec 31, 2022
- Completion date
- Dec 31, 2023
- First posted
- Nov 3, 2021
- Last posted
- Nov 3, 2021
- Enrollment
- 1000
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Center for Vascular Pathology, MoscowLead sponsor
- The Vascular Anomalies Center (VAC) "Hemangioma"Study chair
- The Vascular Anomalies Center (VAC) "Hemangioma"Study chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.